Traws Pharma, Inc. (NASDAQ:TRAW – Free Report) – Investment analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Traws Pharma in a note issued to investors on Wednesday, April 3rd. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.24) per share for the quarter. The consensus estimate for Traws Pharma’s current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Traws Pharma’s Q2 2024 earnings at ($0.25) EPS, Q3 2024 earnings at ($0.25) EPS, Q4 2024 earnings at ($0.20) EPS and FY2028 earnings at ($1.16) EPS.
Traws Pharma Stock Down 1.5 %
Shares of TRAW opened at $0.77 on Monday. Traws Pharma has a one year low of $0.55 and a one year high of $1.45. The stock has a market cap of $16.21 million, a price-to-earnings ratio of -0.85 and a beta of 1.37.
About Traws Pharma
Onconova Therapeutics, Inc operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company’s products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib.
See Also
- Five stocks we like better than Traws Pharma
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- 4 Golden Crosses With Double-Digit Upside Ahead
- P/E Ratio Calculation: How to Assess Stocks
- All-Aboard! Greenbrier Companies Breaks Out, New Highs Ahead
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 High Dividend Socks to Replace Lower Savings Yields Ahead
Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
